218 related articles for article (PubMed ID: 24844855)
21. Health technology assessment: principles, methods and current status.
Giovagnoni A; Bartolucci L; Manna A; Morbiducci J; Ascoli G
Radiol Med; 2009 Aug; 114(5):673-91. PubMed ID: 19367465
[TBL] [Abstract][Full Text] [Related]
22. Prioritizing investments in health technology assessment. Can we assess potential value for money?
Davies L; Drummond M; Papanikolaou P
Int J Technol Assess Health Care; 2000; 16(1):73-91. PubMed ID: 10815355
[TBL] [Abstract][Full Text] [Related]
23. Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.
Howard S; Scott IA; Ju H; McQueen L; Scuffham PA
Aust Health Rev; 2019 Oct; 43(5):591-599. PubMed ID: 30205873
[TBL] [Abstract][Full Text] [Related]
24. An equity framework for health technology assessments.
Culyer AJ; Bombard Y
Med Decis Making; 2012; 32(3):428-41. PubMed ID: 22065143
[TBL] [Abstract][Full Text] [Related]
25. The Development of Health Technology Assessment in Asia: Current Status and Future Trends.
Liu G; Wu EQ; Ahn J; Kamae I; Xie J; Yang H
Value Health Reg Issues; 2020 May; 21():39-44. PubMed ID: 31634795
[TBL] [Abstract][Full Text] [Related]
26. Linking the Regulatory and Reimbursement Processes for Medical Devices: The Need for Integrated Assessments.
Ciani O; Wilcher B; van Giessen A; Taylor RS
Health Econ; 2017 Feb; 26 Suppl 1():13-29. PubMed ID: 28139087
[TBL] [Abstract][Full Text] [Related]
27. Health technology assessment and primary data collection for reducing uncertainty in decision making.
Goeree R; Levin L; Chandra K; Bowen JM; Blackhouse G; Tarride JE; Burke N; Bischof M; Xie F; O'Reilly D
J Am Coll Radiol; 2009 May; 6(5):332-42. PubMed ID: 19394574
[TBL] [Abstract][Full Text] [Related]
28. The impact of the National Institute for Health Research Health Technology Assessment programme, 2003-13: a multimethod evaluation.
Guthrie S; Bienkowska-Gibbs T; Manville C; Pollitt A; Kirtley A; Wooding S
Health Technol Assess; 2015 Aug; 19(67):1-291. PubMed ID: 26307643
[TBL] [Abstract][Full Text] [Related]
29. Hard choices: Reflections from the tomb of the unknown patient.
McCabe C; Round J
Healthc Manage Forum; 2019 Nov; 32(6):288-292. PubMed ID: 31505957
[TBL] [Abstract][Full Text] [Related]
30. Early assessment of medical technologies to inform product development and market access: a review of methods and applications.
Ijzerman MJ; Steuten LM
Appl Health Econ Health Policy; 2011 Sep; 9(5):331-47. PubMed ID: 21875163
[TBL] [Abstract][Full Text] [Related]
31. Is the National Institute for Health and Care Excellence (NICE) in England more 'innovation-friendly' than the Federal Joint Committee (G-BA) in Germany?
Schaefer R; Schlander M
Expert Rev Pharmacoecon Outcomes Res; 2019 Aug; 19(4):453-462. PubMed ID: 30556745
[No Abstract] [Full Text] [Related]
32. HTA Implementation Roadmap in Central and Eastern European Countries.
Kaló Z; Gheorghe A; Huic M; Csanádi M; Kristensen FB
Health Econ; 2016 Feb; 25 Suppl 1(Suppl Suppl 1):179-92. PubMed ID: 26763688
[TBL] [Abstract][Full Text] [Related]
33. Value assessment of disease-modifying therapies for Relapsing-Remitting Multiple Sclerosis: HTA evidence from seven OECD countries.
Visintin E; Tinelli M; Kanavos P
Health Policy; 2019 Feb; 123(2):118-129. PubMed ID: 30227974
[TBL] [Abstract][Full Text] [Related]
34. [The role of HTA in German health care. Do we need impact objectives?].
Gerhardus A
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Mar; 49(3):233-40. PubMed ID: 16453136
[TBL] [Abstract][Full Text] [Related]
35. Health technology assessment: a review of international activity and examples of approaches with computed tomographic colonography.
Husereau D; Morrison A; Battista R; Goeree R
J Am Coll Radiol; 2009 May; 6(5):343-52. PubMed ID: 19394575
[TBL] [Abstract][Full Text] [Related]
36. The Development of the Romanian Scorecard HTA System.
Radu CP; Chiriac ND; Pravat AM
Value Health Reg Issues; 2016 Sep; 10():41-47. PubMed ID: 27881276
[TBL] [Abstract][Full Text] [Related]
37. Disinvestment in healthcare: an overview of HTA agencies and organizations activities at European level.
Calabrò GE; La Torre G; de Waure C; Villari P; Federici A; Ricciardi W; Specchia ML
BMC Health Serv Res; 2018 Mar; 18(1):148. PubMed ID: 29490647
[TBL] [Abstract][Full Text] [Related]
38. Formal Implementation of Cost-Effectiveness Evaluations in Japan: A Unique Health Technology Assessment System.
Hasegawa M; Komoto S; Shiroiwa T; Fukuda T
Value Health; 2020 Jan; 23(1):43-51. PubMed ID: 31952673
[TBL] [Abstract][Full Text] [Related]
39. Expanding Health Technology Assessments to Include Effects on the Environment.
Marsh K; Ganz ML; Hsu J; Strandberg-Larsen M; Gonzalez RP; Lund N
Value Health; 2016; 19(2):249-54. PubMed ID: 27021760
[TBL] [Abstract][Full Text] [Related]
40. How to Appropriately Extrapolate Costs and Utilities in Cost-Effectiveness Analysis.
Bojke L; Manca A; Asaria M; Mahon R; Ren S; Palmer S
Pharmacoeconomics; 2017 Aug; 35(8):767-776. PubMed ID: 28470594
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
